Drugs / GDC-4198
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07100106 | Oct 2025 → Aug 2028 expected | breast cancer | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GDC-4198 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07100106 ↗ |
| Route | Oral | “GDC-4198 will be administered orally.” NCT07100106 ↗ |